Biogen Inc. Files 8-K: Other Events & Exhibits

Ticker: BIIB · Form: 8-K · Filed: 2025-05-12T00:00:00.000Z

Sentiment: neutral

Topics: disclosure, regulatory-filing

Related Tickers: BIIB

TL;DR

Biogen filed an 8-K on May 6th, check for updates.

AI Summary

Biogen Inc. filed an 8-K on May 12, 2025, reporting an event that occurred on May 6, 2025. The filing pertains to 'Other Events' and includes 'Financial Statements and Exhibits'. Specific details regarding the nature of the event or any financial figures were not provided in the excerpt.

Why It Matters

This filing indicates a material event or update from Biogen Inc. that requires disclosure to investors and the public.

Risk Assessment

Risk Level: low — The filing is a standard disclosure form without immediate negative or positive financial implications presented in the excerpt.

Key Players & Entities

FAQ

What specific event is reported under 'Other Events'?

The provided excerpt does not specify the nature of the 'Other Events' reported by Biogen Inc.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on May 6, 2025.

What is Biogen Inc.'s principal executive office address?

Biogen Inc.'s principal executive offices are located at 225 Binney Street, Cambridge, Massachusetts 02142.

What is the filing date of this 8-K report?

This 8-K report was filed on May 12, 2025.

What is Biogen Inc.'s standard industrial classification?

Biogen Inc.'s standard industrial classification is BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836].

From the Filing

0001193125-25-117854.txt : 20250512 0001193125-25-117854.hdr.sgml : 20250512 20250512164512 ACCESSION NUMBER: 0001193125-25-117854 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20250506 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250512 DATE AS OF CHANGE: 20250512 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOGEN INC. CENTRAL INDEX KEY: 0000875045 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 330112644 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19311 FILM NUMBER: 25935594 BUSINESS ADDRESS: STREET 1: 225 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 7814642000 MAIL ADDRESS: STREET 1: 225 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: BIOGEN IDEC INC. DATE OF NAME CHANGE: 20070427 FORMER COMPANY: FORMER CONFORMED NAME: BIOGEN IDEC INC DATE OF NAME CHANGE: 20031112 FORMER COMPANY: FORMER CONFORMED NAME: IDEC PHARMACEUTICALS CORP / DE DATE OF NAME CHANGE: 19970530 8-K 1 d13940d8k.htm 8-K 8-K false 0000875045 0000875045 2025-05-06 2025-05-06     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTIONS 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 6, 2025     BIOGEN INC. (Exact name of registrant as specified in its charter)       Delaware   0-19311   33-0112644 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.) 225 Binney Street , Cambridge , Massachusetts 02142 (Address of principal executive offices; Zip Code) Registrant’s telephone number, including area code: (617) 679-2000 Not Applicable (Former name or former address, if changed since last report.)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.0005 par value   BIIB   The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 8.01 Other Events. On May 6, 2025, Biogen Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with BofA Securities, Inc., Citigroup Global Markets Inc. and J.P. Morgan Securities LLC, as representatives of the several underwriters named in Schedule I thereto, relating to the issuance and sale of $1.75 billion aggregate principal amount of notes, consisting of $400 million aggregate

View on Read The Filing